Press Releases

  • Nycomed files marketing authorisation application for an intranasal fentanyl spray in Europe

    07.12.2007

    Marketing authorisation application filed for Europe through the Centralised Procedure Treatment aimed at opioid tolerant patients with cancer experiencing breakthrough pain Strengthening the Nycomed pain control portfolio
  • Nycomed significantly increases profitability

    19.11.2007

    Net turnover increases by 4.9% for the first nine months of 2007 29.4% increase in adjusted EBITDA Strong margin growth and reduced spending Integration of Altana Pharma ahead of plan with positive effect on business opportunities and spending levels Bid for Bradley Pharmaceuticals Teduglutide in-licensed
  • Nycomed signs definitive agreement to acquire Bradley Pharmaceuticals, Inc., strengthening US specialty business

    30.10.2007

    Acquisition will add to the branded dermatologic line as a growth driver for the future Integration of Bradley will provide an enhanced platform for in-licensing and co-promotion of dermatology products Bradley Pharmaceuticals will be integrated with the PharmaDerm and Fougera divisions of Nycomed’s US specialty business Combined sales of Nycomed US and Bradley amount to approximately €320 million/$450 million on an annualised basis
  • Nycomed and NPS Pharmaceuticals Announce Licensing Agreement for GATTEX™

    26.09.2007

    Nycomed acquires exclusive rights outside North America GATTEX™ matches Nycomed’s capabilities in gastroenterology Total upfront payments of $35 million and potential for more than $150 million milestone payments
  • Nycomed and Wyeth Continue Lawsuit to Defend Patent for Pantoprazole

    07.09.2007

    Nycomed and its licence holder Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced today that the United States District Court for the District of New Jersey denied Nycomed’s and Wyeth’s motion for a preliminary injunction against Teva Pharmaceuticals USA, Inc. and Sun Pharmaceuticals Inc. seeking to prevent the launch of a generic version of Protonix® (pantoprazole sodium) prior to resolution of ongoing patent litigation between the parties. The case will now proceed to trial.
  • Nycomed H1 results 2007

    22.08.2007

    The financial results reported in this press release are related to Nycomed S.C.A. SICAR and comprises all of the Nycomed Group’s operations including the ALTANA Pharma activities acquired in December 2006. Comparison figures for H1 2006 are pro-forma and un-audited. A full interim report is available under http://www.nycomed.com/investors/financials
  • US-Court Takes Matter of Motion for Preliminary Injunction for Protonix Under Advisement

    01.08.2007

    Nycomed and its licence holder Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced today that the United States District Court for the District of New Jersey has taken the matter of Wyeth and Nycomed’s motion for a preliminary injunction against Teva Pharmaceuticals USA, Inc. and Sun Pharmaceuticals Inc. in regard to a potential launch of a generic version of Protonix® (pantoprazole sodium) under advisement. The court obtained a commitment from both Teva and Sun not to launch any potential generic version of pantoprazole before September 7, 2007 while it considers the matter.
  • Nycomed expands Preotact® deal

    10.07.2007

    Nycomed and its partner NPS Pharmaceuticals announced today that they have entered an agreement expanding and amending rights and responsibilities under the Preotact® (full-length parathyroid hormone [PTH 1-84]) license originally entered into in 2004. Under the new agreement, Nycomed will gain the right to commercialize Preotact in all ex-US territories, excluding Japan, for which NPS retains commercial rights and Israel, which is the subject of a pre-existing distribution agreement with Neopharm.
  • Nycomed to market Circadin® for primary insomnia

    06.07.2007

    Today Nycomed announced that its partner Neurim Pharmaceuticals EEC, the EU subsidiary of Neurim Pharmaceuticals Ltd has received a European Marketing Authorisation for Circadin® 2 mg (prolonged release melatonin). Circadin® 2 mg is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.
  • Nycomed headquarters established in Zurich, Switzerland

    11.06.2007

    Nycomed has moved into new corporate headquarters in Zurich and the Company’s headquarters function is now officially transferred from Denmark to Switzerland. The new headquarters will be base for the majority of Nycomed’s central function heads and core teams, such as CEO, Integration, Commercial Operations, Legal, Human Resources, Business Development, Communications and Finance/Procurement. Employees from corporate functions in Denmark and Germany have already started relocation to Zurich.
  • Venticute® granted “Fast Track” designation in the US

    01.06.2007

    Nycomed’s investigational surfactant product Venticute® (rSP-C- Surfactant) has been granted “Fast Track” designation by the United States Food and Drug Administration for reduction of mortality in patients with severe acute pneumonia or aspiration of gastric contents leading to intubation, mechanical ventilation and severe oxygenation impairment.
  • Nycomed Q1 results 2007

    29.05.2007

    The financial results reported in this press release are related to Nycomed S.C.A. SICAR and comprises all of the Nycomed Group’s operations including the ALTANA Pharma activities acquired in December 2006. Comparison figures for Q1 2006 are pro-forma and un-audited. A full interim report is available under www.nycomed.com/investors/financials
  • Nycomed and Micromet Enter Into Exclusive Worldwide Collaboration to Develop and Commercialize anti-GM-CSF Antibodies for the Treatment of Inflammatory and Autoim-mune Diseases

    24.05.2007

    Nycomed and Micromet, Inc. (Nasdaq: MITI) today announced an agreement under which the two companies will collaborate on the development of anti-GM-CSF antibodies that may be useful for the treatment of inflammatory and autoim-mune diseases. The lead product candidate in the collaboration is Micromet’s MT203, a human antibody which neutralizes granulocyte macrophage colony-stimulating factor (GM-CSF), a cytokine known to play a significant role in auto-immune and inflammatory disease. Preclinical studies performed by Micromet support the development and evaluation of MT203 for the treatment of rheuma-toid arthritis, multiple sclerosis, psoriasis, asthma and chronic obstructive pulmo-nary...
  • Alvesco product rights in the US return to Nycomed

    03.05.2007

    Nycomed will take back the Alvesco® product rights from sanofi-aventis, the co-development and marketing partner for the US market. The collaboration with sanofi-aventis for the development and commercialization of the combination product of ciclesonide with formoterol in the US continues.Nycomed is committed to pursue the development of Alvesco® for the US. Following its out-licensing strategy for the US, Nycomed will search for a suitable partner for commercialization of Alvesco® in the US.
  • Nycomed annual results 2006

    04.04.2007

    The financial results reported in this press release are related to Nycomed A/S, which, through its subsidiaries and affiliates, comprises all of the Nycomed Group’s operations. A full annual report is available under www.nycomed.com | investors | financials.
  • ACUITY one-year findings meet all primary endpoints in favour of Angiox® (bivalirudin) alone treatment group

    27.03.2007

    Major bleeding in patients treated for Acute Coronary Syndromes (ACS) nearly triples the risk of death at one year.
  • Nycomed announces integration programme

    21.03.2007

    Today Nycomed provided information about the framework for the group integration following the acquisition of ALTANA Pharma AG. With the planned restructuring measures, Nycomed adjusts to a changing market and prepares for the future. Today’s announcement included details on the strategic realignment, on targeted synergies and on organisational change in different parts of Nycomed. The overall number of redundancies amounts to 1,250 which is approx. 10% of the total workforce of the group.
  • Nycomed officially launched as combined group

    15.01.2007

     Today Nycomed announced the official launch of the combined group following the acquisition of ALTANA Pharma AG which was completed on 31 December 2006. Nycomed will now focus on integrating the two companies, while ensuring that the high level of customer service is maintained. Today’s launch marks the beginning of the active phase of integrating the two companies.
 

Top of page

Takeda Pharma